Edwards Lifesciences Corp... (EW)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Edwards Lifesciences Corporation Statistics
Share Statistics
Edwards Lifesciences Corporation has 589.80M shares outstanding. The number of shares has increased by -1.91% in one year.
Shares Outstanding | 589.80M |
Shares Change (YoY) | -1.91% |
Shares Change (QoQ) | -2.09% |
Owned by Institutions (%) | 79.19% |
Shares Floating | 577.70M |
Failed to Deliver (FTD) Shares | 1.08K |
FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 9.04M, so 1.53% of the outstanding shares have been sold short.
Short Interest | 9.04M |
Short % of Shares Out | 1.53% |
Short % of Float | 1.56% |
Short Ratio (days to cover) | 1.81 |
Valuation Ratios
The PE ratio is 32.99 and the forward PE ratio is 29.66. Edwards Lifesciences Corporation's PEG ratio is -5.41.
PE Ratio | 32.99 |
Forward PE | 29.66 |
PS Ratio | 7.7 |
Forward PS | 5.2 |
PB Ratio | 6.96 |
P/FCF Ratio | 73.49 |
PEG Ratio | -5.41 |
Enterprise Valuation
Edwards Lifesciences Corporation has an Enterprise Value (EV) of 45.81B.
EV / Earnings | 32.67 |
EV / Sales | 7.63 |
EV / EBITDA | 25.92 |
EV / EBIT | 29.86 |
EV / FCF | 72.77 |
Financial Position
The company has a current ratio of 3.38, with a Debt / Equity ratio of 0.1.
Current Ratio | 3.38 |
Quick Ratio | 2.4 |
Debt / Equity | 0.1 |
Total Debt / Capitalization | 9.46 |
Cash Flow / Debt | 1.29 |
Interest Coverage | 87.16 |
Financial Efficiency
Return on equity (ROE) is 0.21% and return on capital (ROIC) is 18.12%.
Return on Equity (ROE) | 0.21% |
Return on Assets (ROA) | 0.15% |
Return on Capital (ROIC) | 18.12% |
Revenue Per Employee | 375.30K |
Profits Per Employee | 87.65K |
Employee Count | 16.00K |
Asset Turnover | 0.64 |
Inventory Turnover | 1.18 |
Taxes
Income Tax | 198.70M |
Effective Tax Rate | 0.12 |
Stock Price Statistics
The stock price has increased by -13.77% in the last 52 weeks. The beta is 1.1, so Edwards Lifesciences Corporation's price volatility has been higher than the market average.
Beta | 1.1 |
52-Week Price Change | -13.77% |
50-Day Moving Average | 72.69 |
200-Day Moving Average | 74.79 |
Relative Strength Index (RSI) | 57.97 |
Average Volume (20 Days) | 4.76M |
Income Statement
In the last 12 months, Edwards Lifesciences Corporation had revenue of 6.00B and earned 1.40B in profits. Earnings per share was 2.31.
Revenue | 6.00B |
Gross Profit | 4.63B |
Operating Income | 1.53B |
Net Income | 1.40B |
EBITDA | 1.77B |
EBIT | 1.53B |
Earnings Per Share (EPS) | 2.31 |
Balance Sheet
The company has 1.14B in cash and 694.90M in debt, giving a net cash position of 449.10M.
Cash & Cash Equivalents | 1.14B |
Total Debt | 694.90M |
Net Cash | 449.10M |
Retained Earnings | 8.99B |
Total Assets | 12.97B |
Working Capital | 4.78B |
Cash Flow
In the last 12 months, operating cash flow was 895.80M and capital expenditures -266.30M, giving a free cash flow of 629.50M.
Operating Cash Flow | 895.80M |
Capital Expenditures | -266.30M |
Free Cash Flow | 629.50M |
FCF Per Share | 1.04 |
Margins
Gross margin is 77.02%, with operating and profit margins of 25.55% and 23.35%.
Gross Margin | 77.02% |
Operating Margin | 25.55% |
Pretax Margin | 26.61% |
Profit Margin | 23.35% |
EBITDA Margin | 29.44% |
EBIT Margin | 25.55% |
FCF Margin | 10.48% |
Dividends & Yields
EW does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 3.09% |
FCF Yield | 1.43% |
Analyst Forecast
The average price target for EW is $78, which is 4.4% higher than the current price. The consensus rating is "Hold".
Price Target | $78 |
Price Target Difference | 4.4% |
Analyst Consensus | Hold |
Analyst Count | 21 |
Stock Splits
The last stock split was on Jun 1, 2020. It was a forward split with a ratio of 3:1.
Last Split Date | Jun 1, 2020 |
Split Type | forward |
Split Ratio | 3:1 |
Scores
Altman Z-Score | 10.64 |
Piotroski F-Score | 6 |